Granata Bio Advances Phase III GRACE Study for Investigational Gonadotropin in IVF Treatment
核心洞察
Granata Bio Corporation (搜索) reports strong enrollment momentum in its pivotal Phase III GRACE study evaluating an investigational gonadotropin product for assisted reproductive technology.
The randomized, controlled trial is actively enrolling across leading fertility centers throughout the United States to assess cumulative live birth rates and safety outcomes in women undergoing IVF treatment.
The study aims to provide a new therapeutic option that could expand patient choice and increase access to affordable fertility treatments for those pursuing in vitro fertilization.
Granata Bio Corporation (搜索) announced strong enrollment momentum in its pivotal Phase III clinical study evaluating an investigational gonadotropin product for assisted reproductive technology (ART). The GRACE multicenter study has multiple subjects already screened and is actively enrolling across leading fertility centers throughout the United States.
Study Design and Objectives
The randomized, controlled trial will assess cumulative live birth rates and safety outcomes in women undergoing in vitro fertilization (IVF) treatment. The study's primary goal is to provide a new therapeutic option for patients seeking fertility treatment through IVF procedures.
Dr. John Park from Carolina Conceptions (搜索), who serves as the lead investigator of the Phase III study, emphasized the clinical need being addressed. "As reproductive endocrinologists, we see firsthand the challenges our patients face in accessing effective, affordable fertility treatments," Park said. "We're excited to participate in a study that has the potential to expand patient choice and increase access to care for those pursuing IVF."
Company's Reproductive Health Strategy
Granata Bio's gonadotropin program represents the company's continued commitment to innovation in fertility care, building on proven therapeutic classes while prioritizing modern manufacturing, quality, and accessibility. The biotechnology company, founded in 2018, focuses on developing and accelerating fertility treatments that expand therapeutic choices and improve access and affordability.
Barbara Cometti, PhD, Head of Scientific Affairs at Granata Bio, highlighted the broader implications of the research. "This milestone reflects our commitment to combining innovation with real-world impact," Cometti said. "Beyond advancing our gonadotropin programs, we're also advancing several early-stage programs focused on novel biologics that have the potential to redefine reproductive care."
Pipeline Development
The company credits its deep expertise in fertility, strong strategic partnerships, and commitment to steady progress for driving consistent milestone achievements across its innovative pipeline. Granata Bio aims to shape the future of reproductive health by reimagining what's possible to help build families, with a focus on expanding therapeutic choices and improving access to fertility treatments.